ALXO · XBRL financial data

Alx Oncology Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALXO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,182	0	0	—	—	—
Research and development	28,961	60,170	98,400	141,795	116,373	76,996
General and administrative	14,809	23,385	29,036	28,483	26,094	23,850
Total operating expenses	44,845	83,555	127,436	170,278	142,467	104,021
Operating income (loss)	(43,663)	(83,555)	(127,436)	(170,278)	(142,467)	(104,021)
Interest income	—	91	4,278	10,649	9,366	3,964
Interest expense	—	13	238	1,565	1,729	1,602
Other income (expense)	(1,339)	84	(260)	389	(20)	(36)
Income tax expense (benefit)	241	(21)	64	0	0	0
Net income (loss)	(45,740)	(83,463)	(123,482)	(160,805)	(134,850)	(101,695)
Earnings per share, basic USD per share	(2.76)	(2.07)	(3.03)	(3.74)	(2.58)	(1.90)
Earnings per share, diluted USD per share	(2.76)	(2.07)	(3.03)	(3.74)	(2.58)	(1.90)
Weighted average shares, basic thousands of shares	18,485	40,308	40,700	42,988	52,175	53,658
Weighted average shares, diluted thousands of shares	18,485	40,308	40,700	42,988	52,175	53,658

Fiscal years (ALXO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	434,219	363,667	48,822	22,406	17,567	16,373
Short-term investments	—	—	217,385	160,330	110,190	28,417
Prepaid and other current assets	1,773	3,352	4,762	5,923	6,595	5,937
Total current assets	435,992	367,019	270,969	188,659	134,352	50,727
Property and equipment, net	52	897	3,889	3,589	2,905	1,200
Right-of-use asset	—	1,800	5,626	4,847	4,023	1,159
Total assets	436,054	380,183	306,489	242,553	147,775	59,046
Accounts payable	4	3,764	8,073	8,591	4,497	4,914
Current portion of long-term debt	—	—	0	0	435	5,217
Total current liabilities	6,204	15,295	28,325	36,001	18,500	24,553
Long-term debt	—	—	9,389	9,639	9,469	4,532
Lease liability, non-current	—	1,558	5,258	4,411	3,462	2,561
Total liabilities	6,209	17,134	43,025	52,841	34,157	33,065
Accumulated deficit	(118,522)	(201,985)	(325,467)	(486,272)	(621,122)	(722,817)
Total stockholders' equity	429,845	363,049	263,464	189,712	113,618	25,981
Total liabilities and equity	436,054	380,183	306,489	242,553	147,775	59,046
Common shares outstanding (cover page) thousands of shares	40,127	40,631	40,863	50,152	53,384	131,608

Fiscal years (ALXO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(45,740)	(83,463)	(123,482)	(160,805)	(134,850)	(101,695)
Stock-based compensation	5,436	13,914	23,839	26,273	27,093	12,579
Depreciation and amortization	202	51	342	836	872	706
Net cash from operating activities	(38,289)	(68,101)	(89,223)	(130,364)	(121,912)	(84,142)
Purchases of property and equipment	31	666	1,427	1,274	447	212
Net cash from investing activities	610	(4,923)	(235,416)	44,657	86,256	82,586
Proceeds from issuing common stock	368,256	—	—	—	29,661	1,688
Net cash from financing activities	462,881	2,472	9,860	59,291	30,817	362

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Alx Oncology Holdings	22,687	not reported	(16,057)*	138.3M	8.6 quarters	Q2 FY26 10-QJun 30, 2026
Charlie's Holdings	527	not reported	(383)*	280.6M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Cognition Therapeutics	34,012	not reported	(3,053)*	95.1M	11.1 quarters	Q2 FY26 10-QJun 30, 2026
IGC Pharma	331	265	(1,350)*	103.4M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Ernexa Therapeutics	5,028	not reported	(4,152)*	1.6M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Marker Therapeutics	11,331	not reported	(3,716)*	16.7M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Relmada Therapeutics	11,334	not reported	(9,606)*	106.7M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
CEL-SCI	6,527	not reported	(4,031)*	17.6M	1.6 quarters	Q3 FY26 10-QJun 30, 2026
Lipocine	4,979	190	(3,028)*	8.2M	7.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.